Inhibition of COX‐2‐Mediated Arachidonic Acid Metabolism by FGF21‐PPARα Axis Alleviates Liver Steatosis
Guangsen Xu, Tingting Pan, Guiyun Wang, Feng Qiu, Junlin Leng, Qiyang Feng, Yongguo Xue, Ye Wang, Junwei Zheng, Huiying Lu, Bingyan Han, Suntao Wang, Jie Du, Jiaojian Lv, Baile Wang, Xuebo Pan · 2026
Read Inhibition of COX‐2‐Mediated Arachidonic Acid Metabolism by FGF21‐PPARα Axis Alleviates Liver Steatosis by Guangsen Xu, Tingting Pan, Guiyun Wang, Feng Qiu, Junlin Leng, Qiyang Feng, Yongguo Xue, Ye Wang, Junwei Zheng, Huiying Lu, Bingyan Han, Suntao Wang, Jie Du, Jiaojian Lv, Baile Wang, Xuebo Pan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575766.txt.
Description
Guangsen Xu and co-authors trace a hormone pathway that may drive fatty liver disease. The condition, now called MASLD, involves disturbed handling of arachidonic acid, a fat the body turns into signals. The enzyme COX-2 sits at the heart of that pathway, and its control during the disease was unclear.
Both the hormone FGF21 and COX-2 rose in fatty livers. Mice lacking FGF21 and fed a rich diet made even more COX-2, with worse inflammation, stress damage, and scarring. Restoring FGF21 calmed COX-2 and eased liver injury, working through a partner factor, PPAR-alpha. Blocking COX-2 with a drug copied part of the benefit but not the anti-scarring effect. In patients, a COX-2 product in blood tracked with liver injury.
Catalog record
| CREATOR | Guangsen Xu, Tingting Pan, Guiyun Wang, Feng Qiu, Junlin Leng, Qiyang Feng, Yongguo Xue, Ye Wang, Junwei Zheng, Huiying Lu, Bingyan Han, Suntao Wang, Jie Du, Jiaojian Lv, Baile Wang, Xuebo Pan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |